StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$161.52+0.73 (+0.45%)

Close on Nov 2, 2026Market cap $308.20BP/E 22.6Yield –

Novartis Net Sales in the U.S. by Quarter

Net Sales in the U.S. ($M)

QuarterlyAnnual

Novartis Net Sales in the U.S.: $236M in Q3 2026, up 1.7% from a year earlier.

Latest, Q3 2026
236
Period ended Sep 30, 2026
Change on a year earlier
+1.7%
232 in Q3 2025
History
32 quarters
Since Q4 2018
Sources
32
Documents cited below

Where the Q3 2026 figure comes from

“|| Tafinlar + Mekinist | Oncology | BRAF V600+ metastatic and adjuvant melanoma, advanced non-small cell lung cancer (NSCLC), tumor agnostic with BRAF mutation indication, pediatric low grade glioma (pLGG) | 236 | 2 | 334 | 5 | 6 | 570 | 4 | 4”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K & Form 20-F (Top 20 Brands US / Rest of World).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNet Sales in the U.S. ($M)Year on yearSource
Q3 2026Sep 30, 2026236+1.7%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 2026197-19.9%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 2026170-18.3%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 2025181-23.0%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 2025232+2.2%Novartis Form 6-K (0001114448-25-000003) ↗
Q2 2025Jun 30, 2025246+21.8%Novartis Form 6-K (0001370368-25-000012) ↗
Q1 2025Mar 31, 2025208+13.0%Novartis Form 6-K (0001370368-25-000010) ↗
Q4 2024Dec 31, 2024235+17.5%Novartis Form 6-K (0001370368-25-000007) ↗
Q3 2024Sep 30, 2024227+12.9%Novartis Form 6-K (0001370368-24-000022) ↗
Q2 2024Jun 30, 2024202+3.1%Novartis Form 6-K (0001370368-24-000019) ↗
Q1 2024Mar 31, 2024184-5.2%Novartis Form 6-K (0001370368-24-000017) ↗
Q4 2023Dec 31, 2023200+14.3%Novartis Form 6-K (0001370368-24-000007) ↗
Q3 2023Sep 30, 2023201+14.9%Novartis Form 6-K (0001370368-23-000068) ↗
Q2 2023Jun 30, 2023196+12.6%Novartis Form 6-K (0001370368-23-000059) ↗
Q1 2023Mar 31, 2023194+26.0%Novartis Form 6-K (0001370368-23-000046) ↗
Q4 2022Dec 31, 2022175+8.7%Novartis Form 6-K (0001370368-23-000008) ↗

Breakdown

What makes up net Sales in the U.S.

Cite this data

StockData. (2026). Novartis Net Sales in the U.S. ($M), quarterly Q4 2018–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-tafinlar-mekinist-us-sales

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.